Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 177(6): 1533-40, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9607830

ABSTRACT

A phase I/II dose-ranging open-label 28-day monotherapy study of the safety, pharmacokinetics, and antiviral activity of nelfinavir mesylate (Viracept), an inhibitor of human immunodeficiency virus (HIV)-1 protease, was done in 65 HIV-1-infected subjects. After 28 days, 54 responding subjects entered an open-label extension that allowed for the addition of nucleoside inhibitors of reverse transcriptase and dose escalation to maintain durability. The drug was well-tolerated and demonstrated robust antiviral activity, with demonstrable superiority of the 750 mg and 1000 mg three times daily regimens. Thirty subjects who continued to receive therapy at 12 months attained a persistent 1.6 log10 reduction in HIV RNA, accompanied by a mean increase in CD4 cells of 180-200/mm3. Studies of viral genotype and phenotype after virus rebound revealed that the initial active site mutation allowing for nelfinavir resistance is mediated by a unique amino acid substitution in the HIV-1 protease D30N, which does not confer in vitro phenotypic cross-resistance to the currently available protease inhibitors.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV-1/drug effects , Nelfinavir/therapeutic use , Adult , Anti-HIV Agents/adverse effects , Anti-HIV Agents/pharmacokinetics , CD4 Lymphocyte Count , Drug Evaluation , Drug Resistance, Microbial , Female , Follow-Up Studies , HIV Infections/immunology , HIV Infections/virology , HIV Protease Inhibitors/adverse effects , HIV Protease Inhibitors/pharmacokinetics , HIV-1/enzymology , HIV-1/genetics , Humans , Male , Nelfinavir/adverse effects , Nelfinavir/pharmacokinetics , RNA, Viral
2.
J Clin Psychiatry ; 59(5): 217-24, 1998 May.
Article in English | MEDLINE | ID: mdl-9632030

ABSTRACT

BACKGROUND: The purpose of this randomized double-blind, placebo-controlled study was to compare the efficacy and safety of fluoxetine plus group psychotherapy versus group psychotherapy alone in HIV-seropositive men (based on 1986 CDC classes II, III, and IV.C.2) who had been diagnosed with major depressive disorder (DSM-III-R). METHOD: During a 7-week trial, patients were treated with fluoxetine 20-60 mg or placebo 1-3 capsules per day and were seen in weekly supportive group psychotherapy. In addition, subjects were rated on the 17-item Hamilton Rating Scale for Depression (HAM-D-17), Clinical Global Impressions scales for Improvement (CGI-I) and Severity of Illness (CGI-S), and the short version of the Beck Depression Inventory (BDI-13). Of the 47 patients enrolled in the study, 25 were administered fluoxetine and 22 were given placebo. RESULTS: Subjects who received fluoxetine began to show significantly more improvement than patients who received placebo on both self- and observer-rated scales by the end of the first week of treatment. By endpoint, patients treated with fluoxetine experienced greater mean changes from baseline compared with placebo-treated patients on the HAM-D-17 (12.1 vs. 6.6; F = 6.53, df = 1,45; p < .05) and BDI-13 (5.9 vs. 1.2; F = 5.73, df = 1,45; p < .05), and a greater percentage of fluoxetine-treated patients experienced a > or = 50% in HAM-D-17 scores (64% vs. 23%; chi2= 8.60, df = 1, p < .01). Differences were particularly apparent in subjects whose initial depressive episodes were rated as severe (i.e., HAM-D-17 score > or = 24). Severely depressed patients treated with fluoxetine had an endpoint CGI-I of 1.4 compared with an endpoint CGI-I of 2.7 for patients treated with placebo (F = 6.02, df = 1,11; p < .05). Further, side effects were generally mild and transient. The most frequently noted effects reported by subjects treated with fluoxetine were nausea, dry mouth, headache, and diarrhea, in decreasing order of frequency. CONCLUSION: This study supports the efficacy and safety of fluoxetine over and above group psychotherapy for the treatment of HIV-associated major depression.


Subject(s)
Depressive Disorder/therapy , Fluoxetine/therapeutic use , HIV Seropositivity/epidemiology , Psychotherapy, Group , Adult , Combined Modality Therapy , Comorbidity , Depressive Disorder/drug therapy , Depressive Disorder/epidemiology , Double-Blind Method , Drug Administration Schedule , Fluoxetine/adverse effects , Headache/chemically induced , Headache/epidemiology , Humans , Male , Nausea/chemically induced , Nausea/epidemiology , Patient Dropouts , Placebos , Psychiatric Status Rating Scales , Treatment Outcome
3.
J Clin Microbiol ; 34(12): 3196-202, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8940471

ABSTRACT

The quantification of human immunodeficiency virus type 1 (HIV-1) RNA has facilitated clinical research and expedited the development of antiretroviral drugs. The branched-DNA (bDNA) assay provides a reliable method for the quantification of HIV-1 RNA in human plasma and is considered one of the most reproducible assays ready for use in clinical trials. A series of oligonucleotide probe design and solution changes have been developed to enhance the sensitivity of the bDNA assay while maintaining its performance characteristics. Among the changes incorporated into the enhanced-sensitivity bDNA (ES bDNA) assay to reduce the background level and enhance the signal are the use of shorter overhang sequences of target probes for capture, the cruciform design of target probes for amplification, and the addition of preamplifier molecules. The ES bDNA assay is at least 20-fold more sensitive than the first-generation bDNA assay, yet it maintains a high level of accuracy, linearity, and reproducibility. Further, quantification values obtained with the ES bDNA assay and the first-generation bDNA assay are highly correlated, thus allowing for meaningful comparisons of HIV-1 RNA levels in specimens tested with either assay. The ES bDNA assay may be useful in determining the prognostic value of HIV-1 RNA levels of below 10,000 copies per ml and in assessing the clinical benefit of antiretroviral therapy-induced decreases in plasma HIV-1 RNA sustained at levels of below 10,000 copies per ml.


Subject(s)
HIV-1/isolation & purification , Molecular Probe Techniques , RNA, Viral/blood , Virology/methods , Anti-HIV Agents/therapeutic use , Base Sequence , DNA Probes/genetics , Evaluation Studies as Topic , Genetic Variation , Genotype , HIV Infections/drug therapy , HIV Infections/virology , HIV Protease Inhibitors/therapeutic use , HIV-1/genetics , Humans , Isoquinolines/therapeutic use , Molecular Probe Techniques/statistics & numerical data , Molecular Sequence Data , Nelfinavir , Nucleic Acid Amplification Techniques , RNA, Viral/genetics , Reproducibility of Results , Sensitivity and Specificity , Sulfonic Acids/therapeutic use , Virology/statistics & numerical data
4.
Article in English | MEDLINE | ID: mdl-11362604

ABSTRACT

AIDS: Based on favorable results from a phase I study of AG1343 using oral doses of 800 mg and 400 mg, a new study assessed a 300 mg dose regimen as the starting dose for a 1-month pilot phase II trial in HIV-positive patients with CD4 counts between 200 and 500. One patient was assessed who had been diagnosed in 1994 with HIV and had no prior HIV therapy or current medications. Results from HIV RNA titers, p24 antigen levels, and CD4 counts over a 9 to 14 day period showed increases in CD4 counts and decreases in viral load.^ieng


Subject(s)
Antiviral Agents/therapeutic use , HIV Protease Inhibitors/therapeutic use , CD4 Lymphocyte Count , Clinical Trials as Topic , Dose-Response Relationship, Drug , HIV Infections , HIV-1/genetics , HIV-1/isolation & purification , Male , Nelfinavir , RNA, Viral/blood
5.
J Clin Psychiatry ; 51(12): 497-501, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2258363

ABSTRACT

A chart review of 90 male outpatients was conducted to document the type of depressive symptomatology associated with HIV infection and to review the nature of antidepressant treatment provided in two university-affiliated outpatient settings. Forty-five individuals who tested positive for HIV infection and who were treated with antidepressant medications were compared with a like number of individuals who had no known risk factors as determined by chart review for HIV infection. Although depressive symptoms were generally similar among the two groups, HIV-positive individuals reported greater decreases in sleep and appetite than the HIV-negative comparison group. Overall, imipramine and fluoxetine earned the most favorable efficacy ratings while producing minimal side effect ratings in both HIV-positive and HIV-negative patients. Among the HIV-positive patients, the asymptomatic group had a better response to treatment with antidepressant medications than either the ARC or AIDS patient groups.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Antidepressive Agents/therapeutic use , Depressive Disorder/drug therapy , AIDS-Related Complex/complications , AIDS-Related Complex/psychology , Acquired Immunodeficiency Syndrome/psychology , Adult , Antidepressive Agents/adverse effects , Drug Evaluation , Fluoxetine/adverse effects , Fluoxetine/therapeutic use , HIV Seropositivity/complications , HIV Seropositivity/psychology , Humans , Imipramine/adverse effects , Imipramine/therapeutic use , Male , Medical Records , Middle Aged , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...